Clinical Trial Update: Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Terbium-161 labeled PSMA in Lutetium-177 PSMA-naive prostate cancer patients; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA (Lutetium-177 labeled PSMA radiopharmaceutical)
• Terbium-161 PSMA (Terbium-161 labeled PSMA radiopharmaceutical)

Snippet

Sponsor: Ankara University | Conditions: Prostate Cancer | Phase 2 | Status: NOT_YET_RECRUITING